Collaboration and Outsourcing in Drug Discovery – Presentation
Last month, we had the pleasure of hosting the “Collaboration and Outsourcing in Drug Discovery” Workshop at this year’s Bio2Business BOS Virtual event. The workshop provided an excellent opportunity to explain the TherapeutAix Approach, using science-led collaboration with our network of R&D partners to offer bespoke solutions to challenges. Included in the workshop were talks […]
NASH – Challenges for drug development
It’s International NASH Day – and it’s also a while since we have last discussed NASH on the blog. In fact, even more has changed from the time when our review on NASH was published in 2019 – all 4 Phase III programs that were ongoing at that time (for obeticholic acid, elafibranor, cenicriviroc, and […]
Pitfalls with Oral Drug Administration in IPF
In the first 3 parts of our blog series on targeted delivery in idiopathic pulmonary fibrosis (IPF), we focused on the potential of inhaled delivery and other targeting strategies to deliver efficacy uplifts for agents as an add-on to the standard of care, while minimising the likelihood of additive side effects. In this fourth installment, we highlight […]
Thoughts from the Extracellular Matrix Pharmacology Symposium
Last week the TherapeutAix team participated in the excellent Extracellular Matrix Pharmacology Symposium, hosted by our network partner Nordic Bioscience. This was a 2-day virtual event, with more than 500 scientists attending to share research and discuss all things extracellular matrix (ECM). Here on the blog, we are revisiting 3 points that got us thinking. Correlations with disease: Throughout the meeting, there was data demonstrating that differences in matrix […]
It’s Rare Disease Day
Worldwide, 473 million people suffer from a rare disease1. But every single one of these diseases is not frequent at all – with some just occurring in a handful of patients. Regulatory pathways and incentives for drug development in rare diseases have facilitated the development of drugs for these indications, both by large pharma companies as well as by many biotechs. In today’s blog […]
Targeting Drug Effects in IPF
In the first two parts of our blog series on drug delivery in idiopathic pulmonary fibrosis (IPF), we focused on inhalation. In this third instalment, we showcase alternative approaches to focusing drug effects to the lung. As we mentioned previously, in the future treatment of IPF, new approaches will need to be compatible, at least initially, with the drugs used currently as “standards of care” (SoC). […]
Challenges in inhaled drug therapy
In the first blog of this series1, we highlighted that, despite the potential advantages, there appear to be only a few opportunities pursuing the inhaled route of delivery in IPF. Our perception is that there is a “double whammy” here – a general nervousness in the Pharma and Investor community regarding inhalation per se and […]
Targeted Delivery in IPF: Inhalation Therapy
As part of a four-part series, we are looking at targeted delivery in idiopathic pulmonary fibrosis (IPF). This week, we focus on inhalation therapy after following with interest the progress of the inhaled formulation of pirfenidone (AP01, Avalyn Pharma). This approach delivers high concentrations of a drug already established as an effective oral therapy in […]